Teva VP Ika Abravanel resigns
The 30% drop in Given Imaging's share price during Homi Shamir's seven-year tenure contrasts to Nasdaq's overall 39% gain.
Given Imaging Ltd. (Nasdaq: GIVN; TASE: GIVN) may or may not be up for sale, and there may, or may not, be talks on a deal. The life sciences company, one of the oldest Israeli firms listed on Nasdaq, is finding its feet, and it is not clear where it will end up. What is clear is that its president and CEO of the past seven years, Homi Shamir, has gotten rich while the company's share price lost a third of its value under his stewardship.
Last week, Given Imaging, which has developed and sells the diagnostic PillCam endoscopic camera for the intestinal tract, filed its F-20 report with the US Securities and Exchange Commission (SEC), in which it disclosed Shamir's salary cost. His basic salary totaled $432,640 in 2012, and he received a cash bonus of $515,923. He also received 30,000 vested convertible units, which are currently worth about $500,000. Vested units are free capital compensation, in contrast to options or shares for which a realization fee has to be paid.
An examination by "Globes" found that since Shamir took up his post in April 2006, he has accumulated NIS 30 million in capital. While this amount is not large for a company of Given Imaging's size and accumulated over seven years, but when compared with the yield Shamir has generated for shareholders during his tenure, NIS 30 million might be an amount that ought to cause the company's directors to squirm.
The 30% drop in Given Imaging's share price during Shamir's seven-year tenure contrasts to Nasdaq's overall 39% gain.
The "Globes" investigation also found that Shamir has enjoyed consistent salary and bonus hikes during his tenure, as well as changes in the capital composition from stock option grants to vested stock grants. His starting salary in 2006 was $330,000, rising to $400,000 in 2007, and $416,000 in 2008. During the 2009 credit crisis, he gave up 10% of his salary, but this did not materially affect his circumstances. A year later, he won a 4% pay hike on his early full salary, not the reduced salary of 2009, to $432,640. His cumulative pay hike in 2006-10 was 31%.
Published by Globes [online], Israel business news - www.globes-online.com - on March 11, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013
You comment was recieved and soon will be published.
Load more comments
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.